Article

Implementing Therapy With Opioids in Patients With Cancer

Oscar de Leon-Casasola

opioid, cancer pain
ONF 2008, 35(6), 7-12. DOI: 10.1188/08.ONF.S1.7-12

Purpose/Objectives: To review strategies to optimize the management of chronic pain in patients with cancer, with an emphasis on the role of opioid analgesics.

Data Sources: Published research, articles from a literature review, and U. S. statistics.

Data Synthesis: Treatment for cancer pain remains suboptimal. With the therapies currently available, as much as 90% of cancer pain can be controlled. Opioid analgesics are an important component of pain management in patients with cancer.

Conclusions: The management of cancer pain is a challenging endeavor that requires an understanding of the etiologies of cancer and the types of pain they can produce. Opioid analgesics are a mainstay of treatment for cancer pain. New drug formulations, delivery systems, and strategies, particularly opioid rotation, are available to optimize cancer pain management.

Implications for Nursing: Opioid rotation may be useful for opening the therapeutic window and establishing a more advantageous analgesic-to-toxicity ratio in patients with cancer.

Jump to a section

    References

    Adams, M. P., & Ahdieh, H. (2005). Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs in R&D, 6(2), 91-99.
    Ballantyne, J. C. (2003). Chronic pain following treatment for cancer: The role of opioids. Oncologist, 8(6), 567-575.
    Ballantyne, J. C., & Mao, J. (2003). Opioid therapy for chronic pain. New England Journal of Medicine, 349(20), 1943-1953.
    Bruera, E., Macmillan, K., Hanson, J., & MacDonald, R. N. (1989). The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain, 39(1), 13-16.
    Caraceni, A., Martini, C., Zecca, E., Portenoy, R. K., Ashby, M. A., Hawson, G., et al. (2004). Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliative Medicine, 18(3), 177-183.
    Cherny, N. J., Chang, V., Frager, G., Ingham, J. M., Tiseo, P. J., Popp, B., et al. (1995). Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer, 76(7), 1283-1293.
    Daniell, H. W. (2002). Hypogonadism in men consuming sustained-action oral opioids. Journal of Pain, 3(5), 377-384.
    de Leon-Casasola, O. A., & Lema, M. J. (2003). Cancer pain. In T. J. Healy & P. R. Knight (Eds.), Wylie and Churchill-Davidson's a practice of anesthesia (7th ed., pp. 1255-1265). London: Arnold Publishers.
    Gabrail, N. Y., Dvergsten, C., & Ahdieh, H. (2004). Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Current Medical Research Opinion, 20(6), 911-918.
    Gimbel, J., & Ahdieh, H. (2004). The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesthesia and Analgesia, 99(5), 1472-1477.
    Hale, M. E., Ahdieh, H., Ma, T., & Rauck, R. (2007). Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. Journal of Pain, 8(2), 175-184.
    Krantz, M. J., Kutinsky, I. B., Robertson, A. D., & Mehler, P. S. (2003). Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy, 23(6), 802-805.
    McNicol, E., Horowicz-Mehler, N., Fisk, R. A., Bennett K., Gialeli-Goudas, M., Chew, P. W., et al. (2003). Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. Journal of Pain, 4(5), 231-256.
    Mendelson, J. H., Mendelson, J. E., & Patch, V. D. (1975). Plasma testosterone levels in heroin addiction and during methadone maintenance. Journal of Pharmacology and Experimental Therapeutics, 192(1), 211-217.
    Mercadante, S. (1999). Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer, 86(9), 1856-1866.
    Mercadante, S., & Bruera, E. (2006). Opioid switching: A systematic and critical review. Cancer Treatment Reviews, 32(4), 304-315.
    National Comprehensive Cancer Network. (2007). Clinical practice guidelines in oncology™: Adult cancer pain [v.1.2007]. Retrieved August 1, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf
    Oliver, J. W., Kravitz, R. L., Kaplan, S. H., & Meyers, F. J. (2001). Individualized patient education and coaching to improve pain control among cancer outpatients. Journal of Clinical Oncology, 19(8), 2206-2212.
    Pasternak, G. W. (2001a). Insights into mu opioid pharmacology: The role of mu opioid receptor subtypes. Life Sciences, 68(19-20), 2213-2219.
    Pasternak, G. W. (2001b). The pharmacology of mu analgesics: From patients to genes. Neuroscientist, 7(3), 220-231.
    Payne, R. (1987). Anatomy, physiology, and neuropharmacology of cancer pain. Medical Clinics of North America, 71(2), 153-167.
    Payne, R. (2007). Recognition and diagnosis of breakthrough pain. Pain Medicine, 8(Suppl. 1), S3-S7.
    Purdue Pharma, L. P. (2006). MS Contin® [package insert]. Stamford, CT: Author.
    Sloan, P., Slatkin, N., & Ahdieh, H. (2005). Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Supportive Care in Cancer, 113(1), 57-65.
    Supernaw, R. B. (2001). CYP2D6 and the efficacy of codeine and codeine-like drugs. American Journal of Pain Management, 11, 30-31.
    U. S. Drug Enforcement Administration. (n.d.). Narcotics. Retrieved August 1, 2007, from http://www.usdoj.gov/dea/pubs/abuse/4-narc.htm
    U. S. Food and Drug Administration. (2006). Death, narcotic overdose, and serious cardiac arrhythmias. Methadone hydrochloride (marketed as Dolophine) information. Retrieved August 1, 2007, from http://www.fda.gov/cder/drug/infopage/methadone/default.htm
    U. S. Food and Drug Administration. (2007a). FDA issues second safety warning on fentanyl skin patch. Retrieved September 10, 2008, from http://www.fda.gov/bbs/topics/NEWS/2007/NEW01762.html
    U. S. Food and Drug Administration. (2007b). Fentanyl transdermal system (marketed as Duragesic and generics). Retrieved April 22, 2008, from http://www.fda.gov/medwatch/safety/2007/safety07.htm#Fentanyl
    Vainio, A., Ollila, J., Matikainen, E., Rosenberg, P., & Kalso, E. (1995). Driving ability in cancer patients receiving long-term morphine analgesia. Lancet, 346(8976), 667-670.
    World Health Organization. (1990). Cancer pain relief and palliative care [Technical report series, No. 804]. Geneva, Switzerland: Author.